CVM

CEL-SCI Corporation (CVM) | Rumor.io

CEL-SCI

CVM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,019

Bullish sentiment (50-day avg)23%

Price to earnings ratio-0.28

Market capitalization29.9M

Earnings per share-1.69

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-25.4M

Social

What share of all stock conversation is about CVM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 16

CEL-SCI Corporation has been invited to deliver a keynote address on Multikine at the 6th World Congress on Otology, Rhinology and Laryngology.
The company has determined specific tumor and immune biomarkers that may make Multikine more effective as a first-treatment and increase its potential to extend overall patient survival.
CEL-SCI plans to prospectively select patients based on these biomarkers in its upcoming Confirmatory Registration Study, which has approximately 97% statistical power to detect a survival benefit.

Generated by AI

Sentiment

Of the messages about CVM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	7.59% -38.96	40.39% -20.13
Bearish	—	—	92.41% +38.96	59.61% +20.13

Bullish· Jan 22

$CVM is due for a breakout, having broken its trend and is poised to move above its 50MA and 200MA.
The stock has seen a significant increase in volume, driven by demand, with buyers chasing the higher price.
Short interest in $CVM has decreased, setting the stage for a potential walk-up ahead of news that could send the stock running wild.

Bearish· May 12

CEL-SCI Corporation's CEO, Geert, is accused of being incompetent for not raising more capital in the past, despite having the opportunity to do so.
The company's recent stock offering is seen as a sign of desperation, with the CEO offering a large number of shares at a low price, which may indicate that the company is running out of funds.
The company's financial situation is precarious, with a cash burn of $5M per quarter and a large price tag for a planned trial, which may be difficult to fund, especially given the company's limited cash reserves.

Generated by AI

Topics

Of the messages about CVM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	91.67%	78.36%
Technical Analysis	—	—	8.33%	6.22%
Earnings	—	—	0%	0.34%
Analysts	—	—	0%	5.79%
Controversies	—	—	0%	4.68%
Macro	—	—	0%	4.6%

Earnings· Dec 13

CEL-SCI Corporation ($CVM) is expected to release its earnings report, with some speculating about its potential impact.
Analysts are uncertain about the company's earnings prospects, with one person stating they don't think it will be excellent.
The earnings report is a key event for the company, with investors and traders awaiting its release.

Announcements· Aug 28

CEL-SCI Corporation (CVM) announced a best-efforts public offering of 1,111,200 shares of its common stock at $9.00 per share, expected to raise approximately $10 million in gross proceeds.
The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions.
CEL-SCI shares plummeted 38.19% in after-hours trading to $8.06 following the $10 million public offering priced below market levels.

Technical Analysis· Jul 26

CEL-SCI Corporation ($CVM) has shown a strong chart, with a reversal off the lows and a potential breakout above $2.05.
The stock's momentum trigger is $2.05 for a high break, and it has already broken above this level, but the movement was not ideal, with a few wicks above $2.15.
The bulls are starting to stir for $CVM, with a 5% increase since the initial alert, and the stock is expected to break above resistance levels for further upside potential.

Generated by AI

Community

Of the messages about CVM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	96.75%	87.5%
Newcomers	—	0%	3.25%	12.5%

Regulars· Sep 16

CEL-SCI Corporation has been invited to deliver a keynote address on Multikine at the 6th World Congress on Otology, Rhinology, and Laryngology, highlighting the treatment's potential to extend overall survival in patients with locally advanced disease.
CEL-SCI's upcoming Confirmatory Registration Study will select patients based on specific tumor and immune biomarkers, which the company has determined can identify patients where Multikine is more effective as a first-treatment, increasing its potential to extend overall survival.
CEL-SCI's current cash reserves are expected to last until the end of October, which coincidentally aligns with the timing of the upcoming conference where Geert is hoping to generate a pump that can be diluted off of, according to a skeptical market participant.

Newcomers· Jul 11

The partnership between CEL-SCI Corporation ($CVM) and a leading Saudi Arabian pharma company is driving the stock's momentum, with a potential treatment for head and neck cancer.
The recent news of the partnership and the stock's surge in volume are attracting traders, with some anticipating a breakout and others looking for entry points.
The stock's volatility and frequent halts are causing traders to be cautious, with some viewing the mid-day share offerings as a normal occurrence and others looking for a clear breakout setup.

Generated by AI

News

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.

14d agoYahoo Finance

Cel Sci CEO Geert Kersten purchases $138,000 in shares

1mo agoInvesting.com

Cel-Sci shareholders elect directors and approve compensation plans at annual meeting

1mo agoInvesting.com

CEL-SCI Reports Fiscal Third Quarter 2026 Results

VIENNA, Va., August 17, 2026--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.

1mo agoYahoo Finance

Cel-Sci: Fiscal Q3 Earnings Snapshot

1mo agoYahoo Finance

CEL-SCI publishes study on Multikine cancer treatment biomarkers

1mo agoInvesting.com

Also Discussed

Investors talking about CVM also mention

#	Name	Attention
1	Delcath Systems, Inc.DCTH	0%new
2	Dyne Therapeutics, Inc.DYN	0%new
3	DarkHorse Technologies Inc.ANY	0%new
4	Savara Inc.SVRA	0%new
5	Citius Pharmaceuticals, Inc.CTXR	0%0
6	AVDL - Avadel Pharmaceuticals plc	——
7	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
8	BLPH - Bellerophon Therapeutics, Inc.	——
9	Immix Biopharma, Inc.IMMX	0.03%+0.03
10	GSS - Golden Star Resources Ltd.	——

CEL-SCI Corporation

Healthcare
Biotechnology

CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and other diseases. The company’s current work centers on immune-based treatments designed to help the body recognize and respond to disease, with research and development spanning oncology, autoimmune conditions, and infectious diseases. Its lead programs include Multikine, an investigational therapy for head and neck cancer, and the LEAPS platform, which supports the creation of targeted immune-modulating candidates. CEL-SCI also combines drug discovery, development, and manufacturing capabilities for complex biological substances, making it a specialized participant in the life sciences sector. Headquartered in Vienna, Virginia, CEL-SCI Corporation operates as a research-driven company within the biotechnology market, where its pipeline is aimed at advancing novel therapeutic approaches through immunology.

Website

Location

8229 Boone Boulevard

Vienna, VA, 22182

United States

Social

What share of all stock conversation is about CVM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 16

CEL-SCI Corporation has been invited to deliver a keynote address on Multikine at the 6th World Congress on Otology, Rhinology and Laryngology.
The company has determined specific tumor and immune biomarkers that may make Multikine more effective as a first-treatment and increase its potential to extend overall patient survival.
CEL-SCI plans to prospectively select patients based on these biomarkers in its upcoming Confirmatory Registration Study, which has approximately 97% statistical power to detect a survival benefit.

Generated by AI

Sentiment

Of the messages about CVM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	7.59% -38.96	40.39% -20.13
Bearish	—	—	92.41% +38.96	59.61% +20.13

Bullish· Jan 22

$CVM is due for a breakout, having broken its trend and is poised to move above its 50MA and 200MA.
The stock has seen a significant increase in volume, driven by demand, with buyers chasing the higher price.
Short interest in $CVM has decreased, setting the stage for a potential walk-up ahead of news that could send the stock running wild.

Bearish· May 12

CEL-SCI Corporation's CEO, Geert, is accused of being incompetent for not raising more capital in the past, despite having the opportunity to do so.
The company's recent stock offering is seen as a sign of desperation, with the CEO offering a large number of shares at a low price, which may indicate that the company is running out of funds.
The company's financial situation is precarious, with a cash burn of $5M per quarter and a large price tag for a planned trial, which may be difficult to fund, especially given the company's limited cash reserves.

Generated by AI

Topics

Of the messages about CVM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	91.67%	78.36%
Technical Analysis	—	—	8.33%	6.22%
Earnings	—	—	0%	0.34%
Analysts	—	—	0%	5.79%
Controversies	—	—	0%	4.68%
Macro	—	—	0%	4.6%

Earnings· Dec 13

CEL-SCI Corporation ($CVM) is expected to release its earnings report, with some speculating about its potential impact.
Analysts are uncertain about the company's earnings prospects, with one person stating they don't think it will be excellent.
The earnings report is a key event for the company, with investors and traders awaiting its release.

Announcements· Aug 28

CEL-SCI Corporation (CVM) announced a best-efforts public offering of 1,111,200 shares of its common stock at $9.00 per share, expected to raise approximately $10 million in gross proceeds.
The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions.
CEL-SCI shares plummeted 38.19% in after-hours trading to $8.06 following the $10 million public offering priced below market levels.

Technical Analysis· Jul 26

CEL-SCI Corporation ($CVM) has shown a strong chart, with a reversal off the lows and a potential breakout above $2.05.
The stock's momentum trigger is $2.05 for a high break, and it has already broken above this level, but the movement was not ideal, with a few wicks above $2.15.
The bulls are starting to stir for $CVM, with a 5% increase since the initial alert, and the stock is expected to break above resistance levels for further upside potential.

Generated by AI

Community

Of the messages about CVM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	96.75%	87.5%
Newcomers	—	0%	3.25%	12.5%

Regulars· Sep 16

CEL-SCI Corporation has been invited to deliver a keynote address on Multikine at the 6th World Congress on Otology, Rhinology, and Laryngology, highlighting the treatment's potential to extend overall survival in patients with locally advanced disease.
CEL-SCI's upcoming Confirmatory Registration Study will select patients based on specific tumor and immune biomarkers, which the company has determined can identify patients where Multikine is more effective as a first-treatment, increasing its potential to extend overall survival.
CEL-SCI's current cash reserves are expected to last until the end of October, which coincidentally aligns with the timing of the upcoming conference where Geert is hoping to generate a pump that can be diluted off of, according to a skeptical market participant.

Newcomers· Jul 11

The partnership between CEL-SCI Corporation ($CVM) and a leading Saudi Arabian pharma company is driving the stock's momentum, with a potential treatment for head and neck cancer.
The recent news of the partnership and the stock's surge in volume are attracting traders, with some anticipating a breakout and others looking for entry points.
The stock's volatility and frequent halts are causing traders to be cautious, with some viewing the mid-day share offerings as a normal occurrence and others looking for a clear breakout setup.

Generated by AI

CEL-SCI

Social

Sep 16

Bullish· Jan 22

Bearish· May 12

Earnings· Dec 13

Announcements· Aug 28

Technical Analysis· Jul 26

Regulars· Sep 16

Newcomers· Jul 11

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Cel Sci CEO Geert Kersten purchases $138,000 in shares

Cel-Sci shareholders elect directors and approve compensation plans at annual meeting

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Cel-Sci: Fiscal Q3 Earnings Snapshot

CEL-SCI publishes study on Multikine cancer treatment biomarkers

Also Discussed

CEL-SCI Corporation

Company Information

Location

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Cel Sci CEO Geert Kersten purchases $138,000 in shares

Cel-Sci shareholders elect directors and approve compensation plans at annual meeting

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Cel-Sci: Fiscal Q3 Earnings Snapshot

CEL-SCI publishes study on Multikine cancer treatment biomarkers

Also Discussed

Social

Sep 16

Bullish· Jan 22

Bearish· May 12

Earnings· Dec 13

Announcements· Aug 28

Technical Analysis· Jul 26

Regulars· Sep 16

Newcomers· Jul 11